FIGURE

Fig. 6

ID

ZDB-FIG-211009-29

Publication

He et al., 2021 - Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss

Other Figures

All Figure Page

Back to All Figure Page

Fig. 6

Sirolimus synergizes with venetoclax and S63845 to suppress <italic>nf1/pten</italic>-mutant melanoma tumor growth and extend the survival of tumor-bearing zebrafish.

a Representative sagittal tissue sections from a transplanted nf1/pten-mutant melanoma tumor treated for 2 days with the indicated drugs. Sections were immunostained with antibodies to detect LC3A/B. Left panels: E = eye, B = brain, G = gut, K = kidney, L = liver, S = swim bladder, T = tumor. Right panels: ×63 magnification of tumor cells from the small black boxes in left panels. b–g Transplanted nf1/pten-mutant melanoma tumor cells were monitored daily in 3-week-old rag2^−/− recipient zebrafish treated with DMSO (CTR), venetoclax, S63845, sirolimus, or the drug combinations (n = 11 or 12 for each curve; doses as indicated). Kaplan–Meier curves for PFS (b, d, and f) and OS (c, e, and g) were compared using a log-rank test. Drugs were refreshed every 2 days during the 6-day course of treatment, as indicated by black arrows. h Representative tissue sections from transplanted nf1/pten-mutant melanoma tumors treated for 2 days with DMSO (CTR), 7.5 μM venetoclax and 2.5 μM S63845, 10 μM sirolimus, and the three-drug combination. Sections were immunostained using antibodies to detect PCNA and CC3 and quantified in (i). ns p > 0.05, ***p < 0.0001 by Mann–Whitney test. Scale bars = 20 μm.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Oncogene